Identification of deferasirox as a human xanthine oxidase inhibitor

Yunfei Qi; Xinheng He; Xiaoshan Wu; Tingting Zhou; Ningning Liang; Jiazheng Jiao; Yanhao Chen; Yue Yuan; Yuwei Zhang; Yucheng Wang; Yan Liu; Qiurong Ding

doi:10.1093/lifemedi/lnaf014

Life Medicine ›› 2025, Vol. 4 ›› Issue (2) : lnaf014 DOI: 10.1093/lifemedi/lnaf014

Letter

Identification of deferasirox as a human xanthine oxidase inhibitor

Author information +

History +

PDF (1870KB)

Cite this article

Download citation ▾

Yunfei Qi, Xinheng He, Xiaoshan Wu, Tingting Zhou, Ningning Liang, Jiazheng Jiao, Yanhao Chen, Yue Yuan, Yuwei Zhang, Yucheng Wang, Yan Liu, Qiurong Ding. Identification of deferasirox as a human xanthine oxidase inhibitor. Life Medicine, 2025, 4(2): lnaf014 DOI:10.1093/lifemedi/lnaf014

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Joosten LAB , Crişan TO , Bjornstad P , et al. Asymptomatic hyperuricaemia: a silent activator of the innate immune system. Nat Rev Rheumatol 2020; 16: 75- 86.

[2]	Singh JV , Bedi PMS , Singh H , et al. Xanthine oxidase inhibitors:patent landscape and clinical development (2015-2020). Expert Opin Ther Pat. 2020; 30: 769- 80.

[3]	Massey V , Brumby PE , Komai H . Studies on milk xanthine oxidase. Some spectral and kinetic properties. J Biol Chem 1969; 244: 1682- 91.

[4]	Nishino T , Okamoto K . The role of the[2Fe-2s] cluster centers in xanthine oxidoreductase. J Inorg Biochem 2000; 82: 43- 9.

[5]	Chen Y , Ding Q . Optimized protocols for efficient gene editing in mouse hepatocytes in vivo using CRISPR-Cas9 technology. STAR Protoc 2021; 3: 101062.

[6]	Zhang K , Zhang L , Liu W , et al. In vitro expansion of primary human hepatocytes with efficient liver repopulation capacity. Cell Stem Cell 2018; 23: 806- 19.e4.

[7]	Naderi M , Sadeghi-Bojd S , Valeshabad AK , et al. A prospective study of tubular dysfunction in pediatric patients with Beta thalassemia major receiving deferasirox. Pediatr Hematol Oncol 2013; 30: 748- 54.

[8]	Yacobovich J , Stark P , Barzilai-Birenbaum S , et al. Acquired proximal renal tubular dysfunction in β-thalassemia patients treated with deferasirox. J Pediatr Hematol Oncol 2010; 32: 564- 7.

[9]	Wei HY , Yang CP , Cheng CH , et al. Fanconi syndrome in a patient with β-thalassemia major after using deferasirox for 27 months. Transfusion 2011; 51: 949- 54.